Why is Concord Drugs falling/rising?

As of 01-Jul, Concord Drugs Ltd is experiencing a significant rise in its stock price, currently at Rs 49.47, reflecting an increase of 8.11 or 19.61%. The stock has recently hit a new 52-week high and has outperformed its sector by 19.82%. Over the past four days, it has shown impressive gains of 59.58%, with a notable opening gain of 3.36% today. The stock is trading above all major moving averages and has seen a substantial increase in investor participation, with delivery volume rising by 737.15% against the five-day average. Despite a decline in profits over the past year, the stock is trading at a discount compared to its peers, which may contribute to its attractive valuation.
In the broader market context, Concord Drugs has outperformed the Sensex significantly, with a one-week return of 54.59% compared to the benchmark's 2.00%. This strong performance is indicative of the stock's resilience and investor confidence, especially given its market-beating returns over various time frames. However, it is important to note that the company has shown weak long-term fundamental strength, with a -4.49% CAGR growth in operating profits over the last five years, which could pose risks for future performance. Overall, the combination of recent positive price movements and strong short-term returns against the benchmark suggests a favorable outlook, despite underlying concerns regarding long-term profitability.